Subscribe: Market Wire - Pharmaceuticals and Biotech: Biotech
http://img.marketwire.com/rss/mwPBBI.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announced  announces  company  mar  march  marketwired mar  marketwired march  marketwired  new  today announced  today  year 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Biotech

Marketwired - Biotech



Marketwired - Biotech



Last Build Date: Mon, 27 Mar 2017 10:33:54 EDT

Copyright: Copyright: (C) Marketwired
 



InSphero 3D Liver Microtissues Featured at Annual SOT Meeting as More Sensitive Model for DILI and Mechanistic Toxicity Testing

Mon, 27 Mar 2017 10:31:19 EDT

Customer and company presentations highlight InSphero 3D InSight(TM) Liver Microtissues as superior toxicology screening tool




Ogilvy CommonHealth Worldwide and InTouchMD Announce Partnership

Mon, 27 Mar 2017 09:33:39 EDT

PARSIPPANY, NJ--(Marketwired - Mar 27, 2017) -  Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com) and a WPP Health & Wellness company (NASDAQ: WPPGY) (www.wpp.com), today announced the creation of a formal partnership with InTouchMD (www.intouchmd.com), a leading healthcare marketing and solutions company.




BioStem Technologies, Inc. Announces Issuance of Prescription Drug Repackager Permit for Qualified Pharma Ingredients Inc.

Mon, 27 Mar 2017 09:30:00 EDT

POMPANO BEACH, FL--(Marketwired - Mar 27, 2017) -  BioStem Technologies, Inc. (OTC PINK: BSEM) ("BSEM" or "the company"), an emerging International Biotechnology company, is eager to announce that its Oakland Park, Florida-based subsidiary, Qualified Pharma Ingredients Inc. ("QPI"), has been granted their Prescription Drug Repackager permit from the Florida Department of Business & Professional Regulation.




EnWave Awards Restricted Share Rights to Independent Directors

Mon, 27 Mar 2017 09:00:00 EDT




Sprint CEO Marcelo Claure to Keynote at PegaWorld 2017

Mon, 27 Mar 2017 09:00:00 EDT

Pegasystems' annual conference to explore how technology can empower organizations to achieve new levels of performance and make change a competitive advantage




GeoVax Reports on Vaccine Development Progress

Mon, 27 Mar 2017 09:00:00 EDT

Expanding Pipeline for MVA-VLP Vaccine Platform Includes HIV, Zika, Ebola, Malaria, Hepatitis B and Cancer




Advantis Corp. Expands Product and Distribution Channels

Mon, 27 Mar 2017 09:00:00 EDT

NEWPORT BEACH, CA--(Marketwired - Mar 27, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) is partnering with a new cooperative group that is licensed to operate in San Diego. The cooperative, who will be carrying various expanded Advantis product lines, is a technology based delivery service that delivers medical marijuana to its members anywhere in the city within two hours.




OncBioMune Sales of Bekunis(R) and Cirkused(R) Exceed Forecast by 164 Percent in First Six Months on Market

Mon, 27 Mar 2017 08:30:00 EDT

BATON ROUGE, LA--(Marketwired - March 27, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to inform shareholders that sales in Mexico of the Company's licensed products, Bekunis® for constipation and Cirkused® for stress, exceeded projections during the first six months on the market.




VIVUS, Inc. Reacquires STENDRA(R) (Avanafil) Commercial Rights from Sanofi

Mon, 27 Mar 2017 08:30:00 EDT

VIVUS to Receive Commercial Rights to Africa, the Middle East, Turkey and the Commonwealth of Independent States, Including Russia




Tetra Bio-Pharma Appoints Edward Miller as Vice President, Investor Relations & Corporate Communications

Mon, 27 Mar 2017 08:30:00 EDT

OTTAWA, ONTARIO--(Marketwired - March 27, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), today announced that it entered into an employment agreement with Edward Miller as Vice President, Investor Relations and Corporate Communications effective today.




Golden Leaf Signs Binding Letter of Agreement to Acquire Cannabis Licenses in Nevada

Mon, 27 Mar 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - March 27, 2017) - Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE: GLH) (OTCQB: GLDFF), a leading cannabis oil solutions company built around recognized brands, is pleased to announce that the Company has signed a binding Letter of Agreement (LOA) to acquire a cultivation license and an extraction license in Nevada from NevWa, LLC ("NevWa") (doing business as Grassroots) (the "Transaction").




BriaCell Closes CEO Equity Investment

Fri, 24 Mar 2017 18:22:47 EDT

BERKELEY, CA and VANCOUVER, BC--(Marketwired - March 24, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the "Offering") of 5,612,083 units (the "Units") for aggregate gross proceeds to the Company in the amount of $1,346,900 with its President and CEO, Dr. William Williams.




BioStem Technologies, Inc. Announces Completion of 503b Pharmaceutical and Stem Cell Research Laboratory

Fri, 24 Mar 2017 14:18:03 EDT

OAKLAND PARK, FL--(Marketwired - Mar 24, 2017) -  BioStem Technologies, Inc. (OTC PINK: BSEM) ("BSEM" or "the company"), an emerging International BioTech company, celebrated the opening of its new laboratory and corporate offices with a ribbon cutting ceremony hosted by the BioStem Technologies executive team. BSEM's Founder and CEO, Henry Van Vurst, commented, "With the recent regulation changes we amended our original facility design to comply with FDA 503b regulations, which caused an extension to our timeline, but I couldn't be prouder of this new state-of-the-art facility. Cutting the ribbon with Mayor Lamar Fisher (City of Pompano Beach) was a very proud moment for the entire BSEM team, and it is a testament to how far we have come since the Company's inception in 2014."




Kessler Foundation Renews Collaboration with Children's Specialized Hospital

Fri, 24 Mar 2017 14:08:11 EDT

EAST HANOVER, NJ and NEW BRUNSWICK, NJ--(Marketwired - March 24, 2017) - Kessler Foundation, a global leader in rehabilitation research, and Children's Specialized Hospital, the nation's leading provider of inpatient and outpatient care for children facing special health challenges, have renewed their collaboration by signing a three-year agreement, with a funding level of $2.1 million, to continue their research program for children with disabilities.




GeoVax Reports 2016 Year-End Financial Results

Fri, 24 Mar 2017 14:00:00 EDT

ATLANTA, GA--(Marketwired - Mar 24, 2017) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the year ended December 31, 2016.




NSAV Announces 2.5 Billion Share Reduction

Fri, 24 Mar 2017 10:31:40 EDT

CRESCO, PA--(Marketwired - Mar 24, 2017) - Net Savings Link, Inc. (OTC: NSAV) announced today that the Company has approved a 2.5 billion reduction of its authorized shares. The Company took this action after lengthy consultation with its attorneys, investment bankers and advisers, in order to ensure that the amount of the share reduction benefits all NSAV shareholders, while still allowing the Company to grow and make acquisitions. The Company wants to reassure all of its shareholders that no substantial dilution of its shares has taken place or will take place and that NSAV is not planning or even considering a reverse split of its shares.




Marina Biotech to Present Data on Vascular Resistance and Cancer at the Endocrine Society Annual Meeting on April 1

Fri, 24 Mar 2017 09:10:00 EDT

CITY OF INDUSTRY, CA--(Marketwired - Mar 24, 2017) - Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that a new poster1 on the use of antihypertensive for the treatment of cancer by targeting vascular resistance in the tumor will be presented at the Endocrine Society Annual Meeting to be held on April 1-4, 2017, at Orange County Convention Center, Orlando, FL. 




NetworkNewsWire Announces Publication of Discussion on the Potential of Immunotherapies for Cancer Treatment

Fri, 24 Mar 2017 08:30:00 EDT

NEW YORK, NY--(Marketwired - Mar 24, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring TapImmune, Inc. (NASDAQ: TPIV), an NNW client focused on leading the field of oncology with its next-generation T-cell vaccines and novel immunotherapy platforms.




Chiesi USA, Inc. Earns Triangle Business Journal's Corporate Philanthropy Award

Fri, 24 Mar 2017 08:00:00 EDT

"Chiesi in the Community" corporate social responsibility program impacts local groups, patients and employees




The Modernization of eCOA Technology for Clinical Trials, New Webinar Hosted by Xtalks

Fri, 24 Mar 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - March 24, 2017) - During a live session, mobile health solution expert Mike Hughes, Senior Director of eCOA Solutions from YPrime, will provide a timely update on new industry expectations of eCOA technologies. Next generation eCOA platforms have recently evolved to support sophisticated data collection, simplify management from sponsors and sites, and improve patient compliance.




Medigus Announces $7.5 Million Public Offering

Fri, 24 Mar 2017 07:26:11 EDT

OMER, ISRAEL--(Marketwired - Mar 24, 2017) -  Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced the pricing of a best efforts public offering of 979,714 Class A Units at a purchase price per unit of $3.50 and of 1,163,144 Class B Units at an effective purchase price per unit of $3.50. Each Class A unit consists of (i) one American Depositary Share, or ADS, and (ii) one Series A warrant to purchase one ADS, and each Class B unit consists of (i) one pre-funded warrant to purchase one ADS, and (ii) one Series A warrant to purchase one ADS. The offering is expected to result in gross proceeds to the company of approximately $7.5 million.




Immunovaccine to Present New Pre-clinical Combination Therapy Data at the AACR Annual Meeting

Fri, 24 Mar 2017 07:05:00 EDT

Study Designed to Assess Synergies of Combining DepoVax(TM)-based Cancer Vaccines and Novel Monoclonal Antibody Immunotherapies




Tiziana Life Sciences PLC: Exercise of Warrants & Issue of Equity

Fri, 24 Mar 2017 05:10:52 EDT

LONDON, UNITED KINGDOM--(Marketwired - Mar 24, 2017) - Tiziana Life Sciences PLC (AIM: TILS)




HCi Viocare Ships its 4th Generation Athletic Smart Insole

Thu, 23 Mar 2017 16:00:00 EDT

GLASGOW, SCOTLAND--(Marketwired - Mar 23, 2017) - HCi Viocare (OTCQB: VICA) is pleased to announce that its wholly owned subsidiary HCi Viocare Technologies, the company behind the revolutionary sensing technology FlexisenseT,  has started shipping its 4th Generation Athletic Smart insoles to the sports shoes manufacturers with whom the company is in discussions.




SNS FiRe Conference Names ElpisEremo a 2017 FiReStarter Company

Thu, 23 Mar 2017 15:13:20 EDT

Global thought leaders converge this October to address some of the world's greatest challenges




Pressure BioSciences, Inc. Significantly Expands Marketing and Sales Capabilities

Thu, 23 Mar 2017 10:27:22 EDT

Company Engages Highly-Regarded Lead Generation Service and Hires the First Two of Four Field Sales Directors, Executing on its Plan to Aggressively Enhance Product Sales Capabilities in 2017




Endonovo Therapeutics Files a New Patent Application on Method to Treat Tissues and Organs Using Its Non-Invasive Electroceutical Technology

Thu, 23 Mar 2017 09:29:00 EDT

Company Provides Update on The Development of Its Pipeline of Non-Invasive Electroceuticals Targeting Vascular Diseases and Ischemia/Reperfusion Injuries




Predictive Technology Group, Inc. (PRED) Announces Development Progress of its Non-Invasive DNA Test for Endometriosis in Three Scientific Presentations

Thu, 23 Mar 2017 09:15:00 EDT

Development of the ARTGuide(R) Test for Endometriosis Test Will Rapidly Accelerate Short and Long-Term Company Growth




PCI Synthesis Wins Big at 2017 Life Science Leader Magazine CMO Leadership Awards

Thu, 23 Mar 2017 09:14:00 EDT

Wins "Top Performer" in all 14 categories




Spirax Sarco gives back to help children rebuild their lives around the world

Thu, 23 Mar 2017 09:00:00 EDT

BLYTHEWOOD, SC--(Marketwired - March 23, 2017) - Spirax Sarco, the leader in products and services for steam system management hosted their annual charity event at the Westin Hotel in Savannah, GA on Saturday, March 11, 2017 where participants built prosthetic hands for children in third-world countries who are missing limbs.




Mount Tam Biotechnologies Announces that the Japan Patent Office Has Allowed a Key Patent for Lead Compound TAM-01

Thu, 23 Mar 2017 09:00:00 EDT

NOVATO, CA--(Marketwired - Mar 23, 2017) -  Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors is pleased to announce that the Japanese Patent Office has allowed a key patent for TAM-01, a novel mTOR modulator, targeting unmet need in systemic lupus erythematosus (SLE). The patent, owned by the Buck Institute for Research on Aging and licensed exclusively to Mount Tam Biotechnologies, provides composition of matter protection for Mount Tam's lead compound in Japan, complementing Mount Tam's strong intellectual property position in the United States.




Atossa Genetics Opens Enrollment in Study of Endoxifen

Thu, 23 Mar 2017 08:41:12 EDT

SEATTLE, WA--(Marketwired - Mar 23, 2017) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has opened enrollment of a Phase 1 study of endoxifen, which is an active metabolite of tamoxifen, an FDA approved drug for breast cancer. The objectives of this placebo-controlled, repeat dose study of 48 healthy female volunteers is to assess the pharmacokinetics of proprietary formulations of both oral and topical endoxifen dosage forms over 28 days, as well as to assess safety and tolerability.




Avid Bioservices Receives Mutliple 2017 CMO Leadership Awards for Quality, Reliability, Capabilties, Expertise and Compatibility

Thu, 23 Mar 2017 08:05:00 EDT

TUSTIN, CA--(Marketwired - Mar 23, 2017) - Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced that the company has been named a recipient of the 2017 Contract Manufacturing Organization (CMO) Leadership Awards. Presented by the industry publication Life Science Leader and based on market research and surveys conducted by Industry Standard Research (ISR), these awards are intended to honor those companies in the contract manufacturing space that provide their customers with the industry's highest level of service. Now in its 6th year, Life Science Leader's CMO Leadership Awards aim to provide industry insiders with accurate and reliable customer feedback to assist them in choosing a reputable partner for their development and manufacturing needs.




Aeolus Receives BARDA Decision Regarding Additional Options for Lung ARS Development Contract; Files Response to Assertions Made by BARDA in the Notification

Thu, 23 Mar 2017 08:00:00 EDT

MISSION VIEJO, CA--(Marketwired - March 23, 2017) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)




Upcoming Webinar Assessing NASH: Discover the Non-Invasive Techniques

Thu, 23 Mar 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - March 23, 2017) - On Thursday, April 13, 2017, Xtalks will host a complimentary webinar featuring Dr. Richard Ehman, Professor of Radiology, Blanche R. & Richard J. Erlanger Professor of Medical Research, Mayo Clinic; President and CEO, Resoundant, Inc. and Jonathan Riek, Vice President, Musculoskeletal and Metabolic Imaging, BioTelemetry Research (Cardiocore & VirtualScopics) as the presenters.




Critical CRO Oversight Metrics: How to Establish the Right Metrics and Monitor them in Real-time, New Webinar Hosted by Xtalks

Thu, 23 Mar 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - March 23, 2017) - Julie Peacock from Client Services at Comprehend and Linda Sullivan, Co-Founder & President of Metrics Champion Consortium (MCC) will provide an in-depth look at CRO oversight and risk management best practice. Their presentation delves into the gaps in oversight processes, the causes of these gaps and how to successfully address them. The live broadcast takes place on Wednesday, April 12, 2017 at 1pm EDT.




Pieris Pharmaceuticals Reports Full-Year 2016 Financial Results and Corporate Update

Wed, 22 Mar 2017 20:18:32 EDT

Company to Host an Investor Conference Call on Thursday, March 23, 2017 at 10:00 AM EDT




CV Sciences, Inc. Applauds U.S. Department of Defense Smokeless Tobacco Cessation Campaign

Wed, 22 Mar 2017 19:00:00 EDT

Company Addresses its Lead Drug Candidate Aimed at a $2B Market Opportunity




Immunotec conclut une entente afin d'être acquise

Wed, 22 Mar 2017 16:32:45 EDT

VAUDREUIL-DORION, QUÉBEC--(Marketwired - 22 mars 2017) - Immunotec Inc. (TSX CROISSANCE:IMM) (« Immunotec » ou la « société ») a annoncé aujourd'hui qu'elle avait conclu une convention définitive (la « convention d'arrangement ») avec 1111267 B.C. ltée, une filiale d'Immuno Holding S.A. de C.V. (« Immuno Holding ») aux termes de laquelle Immuno Holding devrait acquérir la totalité des actions ordinaires émises et en circulation de la société (les « actions ») en échange d'une contrepartie au comptant de 0,485 $ par action (l'« opération »). La contrepartie représente une prime de 22,8 % par rapport au cours de clôture des actions à la Bourse de croissance TSX (la « Bourse ») le 21 mars 2017 et de 22.4 % par rapport au cours moyen pondéré en fonction du volume des actions à la Bourse pendant la période de 20 jours se terminant le 21 mars 2017.




Immunotec Enters Into Agreement to Be Acquired

Wed, 22 Mar 2017 16:25:45 EDT

VAUDREUIL-DORION, QUEBEC--(Marketwired - March 22, 2017) - Immunotec Inc. (TSX VENTURE:IMM) ("Immunotec" or the "Company") announced today that it has entered into a definitive agreement (the "Arrangement Agreement") with 1111267 B.C. Ltd., a subsidiary of Immuno Holding S.A. de C.V. ("Immuno Holding"), pursuant to which Immuno Holding is expected to acquire all of the issued and outstanding common shares of the Company ("Shares") for a cash consideration of $0.485 per Share (the "Transaction"). The consideration represents a premium of 22.8% to the closing price of the Shares on the TSX Venture Exchange (the "Exchange") on March 21, 2017 and of 22.4% to the volume weighted average trading price of the Shares on the Exchange for the 20-day period ending on March 21, 2017.




Pressure BioSciences, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Provides Business Update

Wed, 22 Mar 2017 12:34:20 EDT

55% Growth in Q4 2016 Products & Services Revenue, Including 70% Increase in Sale of Consumable Supplies, Helps Company Achieve 27% Growth in Products & Services Revenue for Fiscal Year 2016

New Product Releases and Expansion of Sales & Marketing Capabilities Expected to Augment Revenue in FY2017

Investor Conference Call Scheduled for Wednesday, March 22, 2017 at 4:30 PM EDT




DNA testing at BC community pharmacies comes one step closer

Wed, 22 Mar 2017 12:30:00 EDT

Research project focuses on patients on mental health medications




Science Exchange Named Finalist for Coveted Procurement Leaders World Procurement Awards

Wed, 22 Mar 2017 11:00:00 EDT

Science Exchange on Shortlist for Procurement Service Provider Award; Winners Announced in May




Cyrex Laboratories Unveils Array 22 in Canada for Unprecedented Accuracy in Assessing SIBO

Wed, 22 Mar 2017 10:30:00 EDT

New Serum Test Identifies Small Intestine Bacterial Overgrowth (SIBO) to Help Treat Patients Suffering from Irritable Bowels, Malabsorption, Fatigue and More




Osage University Partners Announces A New Hire and Promotion

Wed, 22 Mar 2017 10:00:00 EDT

BALA CYNWYD, PA--(Marketwired - March 22, 2017) - Osage University Partners, a venture capital fund that invests in university startups, announced today the promotion of Manny Stockman, PhD, to Senior Associate on the tech investment team, and the addition of Anurag Agarwal, PhD, Associate on the life science investment team.




TissueGen Featured in Nature.com Webcast on Innovations in Drug Delivery Technology

Wed, 22 Mar 2017 10:00:00 EDT

TissueGen's ELUTE Fiber Provides Controlled Sustained Delivery of Sensitive Drugs Enabling Nerve Regeneration and Tissue Engineering




Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia

Wed, 22 Mar 2017 09:35:26 EDT

HOUSTON, TX--(Marketwired - March 22, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced its lead candidate, Annamycin (also known as "Liposomal Annamycin"), an anthracycline, has received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).




Advantis Corp. To Introduce New Line of Concentrate-Infused Products, CEO to Be Interviewed on Small Cap Voice

Wed, 22 Mar 2017 09:00:00 EDT

NEWPORT BEACH, CA--(Marketwired - Mar 22, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) is introducing a new line of premium concentrate-infused products that it will make available through its existing business partners, before kicking off a new marketing campaign. Advantis CEO, Christopher Swartz will comment further on this product line along with providing a future outlook and shareholder update on Small Cap Voice next week.




NEMUS Bioscience and the University of Mississippi Announce Significant Anti-MRSA Synergy Data Utilizing Proprietary Cannabinoid-Based Anti-Infective Platforms

Wed, 22 Mar 2017 08:30:00 EDT

COSTA MESA, CA--(Marketwired - Mar 22, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) and the company's discovery and research partner, the University of Mississippi (UM), today announced that bactericidal synergy was achieved against multiple species of methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic platform. MRSA species tested included community acquired- (CA-MRSA), healthcare-acquired- (HA-MRSA), and mupirocin-resistant (MR-MRSA) strains of MRSA. 




Sipp Industries Forms Distribution Partnership with Wanderport Corporation to Supply Premium Bulk Hemp Seed and Oil

Wed, 22 Mar 2017 08:30:00 EDT

COSTA MESA, CA--(Marketwired - Mar 22, 2017) - Sipp Industries, Inc. (OTC: SIPC), a multifaceted corporation specializing in technology, manufacturing, and distribution of commercial and consumer products, is pleased to announce that upon exploration of their complementary synergies, a partnership was established to supply premium bulk hemp seed and oil for Wanderport's (OTC: WDRP) growing selection of consumer hemp based products and premium CBD and hemp coffee line.




National Brain Tumor Society Launches New Brain Tumor-Specific Clinical Trial Finder

Wed, 22 Mar 2017 08:30:00 EDT

New tool will make it easier for brain tumor patients to find up-to-date information on clinical trials, enabling patients to better engage with medical research and make more informed decisions about their own treatment options in the era of precision medicine




Hemostemix Announces Corporate Updates

Wed, 22 Mar 2017 08:30:00 EDT

BLACKFALDS, ALBERTA--(Marketwired - March 22, 2017) -




Lexaria Introduces TurboCBD(TM) Brand of High Absorption Full Spectrum Hemp Oil Capsules

Wed, 22 Mar 2017 08:05:00 EDT

KELOWNA, BC--(Marketwired - March 22, 2017) - Lexaria Bioscience Corp (OTCQB: LXRP) (CSE: LXX) (CSE: LXX.CN) (CNSX: LXX) (the "Company" or "Lexaria") announces the introduction of the TurboCBDT brand of technologically enhanced, high absorption full spectrum hemp oil capsules. Lexaria's TurboCBDT capsules are specially formulated with the finest American Ginseng and Ginkgo Biloba for support of enhanced focus and memory, and reduced stress and fatigue.




Aldeyra Therapeutics Schedules Webcast and Conference Call for Full Year 2016 Financial Results

Wed, 22 Mar 2017 08:00:00 EDT

LEXINGTON, MA--(Marketwired - Mar 22, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced it will issue financial results for the year ended December 31, 2016 on Thursday, March 30, 2017, prior to the market open.




Vaxil Secures Collaboration with Clalit Meir Medical Center for its Lead Product

Wed, 22 Mar 2017 08:00:00 EDT

Collaboration to test MUC1-SP immune therapy using clinical samples from multiple cancer types




AntriaBio Appoints Two Pharmaceutical Executives to its Board of Directors

Wed, 22 Mar 2017 08:00:00 EDT

LOUISVILLE, CO--(Marketwired - March 22, 2017) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical growth company specializing in the development of innovative drug therapies for patients with diabetes and metabolic diseases, announced today the appointment of Tae Hoon Kim and Samir R. Patel, M.D. to its Board of Directors. Mr. Kim and Dr. Patel join AntriaBio's Board as the Company prepares to conduct the first-in-human clinical study for its lead product candidate, AB101, a once-weekly basal insulin in development for patients with type 1 and type 2 diabetes.




Golden Leaf Signs Binding Letter of Agreement to Acquire Leading Oregon Cannabis Business

Wed, 22 Mar 2017 07:00:00 EDT

Canaccord Genuity Toronto to Lead Capital Raise to Fund Acquisition Strategy




Easton Pharmaceuticals Announces Advancing $300,000 Payment To CommonSense Ltd. Paving The Way For The Anticipated Closing Of Exclusive Sub-Distribution Agreement For Product AL-Sense with 2nd Quarter Launch

Wed, 22 Mar 2017 06:00:00 EDT

Announces Regulatory Update On Fast-Track Filing Of Generic Cancer Drug Paclitaxel For The Mexican Market and Latin America




New CertainT(TM) Supply Chain Platform Certifies Authenticity and Origin of Products and Brands

Wed, 22 Mar 2017 05:30:00 EDT

CertainT(TM) integrates molecular tagging, testing, tracking and reporting to elevate supply chain traceability, transparency and trust




A1 Group, Inc. Signs North American Licensing and Distribution Agreement with TREC Beverages, Inc.

Tue, 21 Mar 2017 17:35:03 EDT

FORT LAUDERDALE, FL--(Marketwired - Mar 21, 2017) - A1 Group, Inc. (OTC PINK: AWON) is pleased to announce that it has signed an exclusive North American licensing and distribution agreement with TREC Beverages, Inc. ("TREC Beverages"). TREC Beverages' core portfolio beverage item is the "Slow Cow®" Mind CoolerT. Slow Cow, owned by Boisson Slow Cow, Inc., is currently distributing and developing its products in 20 countries throughout the world. With their award-winning 100% natural infused sparkling water designed to help relax your mind and body, sharpen your mental focus, all without causing drowsiness.




Immunotec Provides an Update on Taxation Matters in Mexico

Tue, 21 Mar 2017 17:29:03 EDT

VAUDREUIL-DORION, QUEBEC--(Marketwired - March 21, 2017) - Immunotec Inc. (TSX VENTURE:IMM), a direct-to-consumer company and a leader in the nutritional industry (the "Company" or "Immunotec"), announced today that it has received a ruling from the Mexican Tax Administration Services (MTAS) confirming that its Immunocal MX and Immunocal Platinum products should be classified for importation purposes in HTS code 2106.10.99, the code originally used by the Company prior to August 2013. This milestone is a positive step towards the resolution of the importation audit matters described in Note 28(ii) of the Company's most recent financial statements.




IntelGenx to Report Fourth Quarter and Full Year 2016 Financial Results on March 28, 2017 - Conference Call to Follow

Tue, 21 Mar 2017 16:30:00 EDT

SAINT-LAURENT, QUEBEC--(Marketwired - March 21, 2017) - IntelGenx Technologies Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), today announced that it will release its fourth quarter and full year 2016 financial results after market close on March 28, 2017.




LogixHealth Publishes Physician-Focused Intelligence Briefing: 2017 Emergency Department Physician Update

Tue, 21 Mar 2017 12:00:00 EDT

BEDFORD, MA--(Marketwired - Mar 21, 2017) - LogixHealth, a leading provider of internet and software enabled coding, billing, analytics and management services for hospital and physician practices nationwide, provides services for millions of Emergency Department (ED) visits nationwide, and has analyzed the implications of the Medicare 2017 Physician Fee Schedule and published its newest physician-focused Intelligence Briefing: 2017 Emergency Department Physician Update.




Average Cost of Training New Medical Information Call Center Agents Tops $16,000

Tue, 21 Mar 2017 10:22:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - March 21, 2017) - The most successful pharmaceutical companies allocate an average $16,900 annually per new call center agent, according to a business intelligence study by life sciences research firm Cutting Edge Information.




NSAV Announces Major Reduction of Authorized Shares

Tue, 21 Mar 2017 10:16:21 EDT

CRESCO, PA--(Marketwired - Mar 21, 2017) - Net Savings Link, Inc. (OTC: NSAV) announced today that the Company has approved a major reduction of its authorized shares. The exact amount of the decrease will finalized in the coming days and will be publicly disclosed in a comprehensive press release within a week. The Company will be consulting with its attorneys, investment bankers and advisers, in order to ensure that the amount of the share reduction benefits all NSAV shareholders, while still allowing the Company to grow and make acquisitions. The current management of NSAV had planned a major reduction of its authorized shares, which was increased by the former management in July 2015. The Company decided to take this action and make this announcement earlier than planned in response to numerous shareholder inquiries, in which the NSAV shareholders were afraid of an immediate and substantial dilution of it shares. The Company wants to reassure all of its shareholders that no substantial dilution of its shares has taken place or will take place.




Investissement de 2,5 millions$ CAD dans Prevtec Microbia en appui au lancement du second vaccin en Union Européenne

Tue, 21 Mar 2017 10:10:21 EDT

MONTRÉAL, QUÉBEC--(Marketwired - 21 mars 2017) - Prevtec Microbia a annoncé aujourd'hui une prise de participation de certains des actionnaires de la Société au montant de 2,5 millions de dollars CAD. Les actionnaires Télésystème Ltée, Desjardins-Innovatech, S.E.C., Grupo Corporativo Fuertes, S.L. et Echo Capital FIER Outaouais, Société en commandite ont participé à cette mise de fonds.




Prevtec Microbia Receives Investment of CAD $2.5 million to support the launch of its second vaccine in the European Union

Tue, 21 Mar 2017 10:08:28 EDT

MONTREAL, QUEBEC--(Marketwired - March 21, 2017) - Prevtec Microbia Inc. is pleased to announce that it received an investment from some of the Company's shareholders in the amount of CAD $2.5 million. Telesystem Ltd, Desjardins-Innovatech, S.E.C., Grupo Corporativo Fuertes, S.L. and Echo Capital FIER Outaouais, Limited Partnership participated in this round.




InCrowd's Janet Kosloff Named a Boston SmartCEO 2017 Future 50 Award Winner

Tue, 21 Mar 2017 09:30:00 EDT

Among 60 Greater Boston companies to be recognized for fast growth, made possible by InCrowd's real-time market intelligence platform




Synthego Announces Modified Synthetic sgRNA -- Critical for Editing Primary and Stem Cells, and other Challenging Cell Types

Tue, 21 Mar 2017 09:02:00 EDT

New product protects against intracellular immune responses and exonuclease attack




Pega deepens its AI capabilities in Pega Sales Automation to help businesses accelerate sales cycles and win more deals

Tue, 21 Mar 2017 09:00:00 EDT

New AI functionality predicts sales probability and suggests the right actions to close more deals




Precision Therapeutic Cancer Vaccine Developer Treos Bio Opens U.S. Headquarters in San Francisco

Tue, 21 Mar 2017 08:15:00 EDT

Names Dong Wei, Ph.D., MBA, as its Chief Operating Officer




ONL Therapeutics Receives Nearly $1.0 Million Grant from National Eye Institute for Continued Advancement of ONL1204 Program

Tue, 21 Mar 2017 08:05:00 EDT

Grant Funding Combined with Recent Financing Will Support Final IND-Enabling Studies for Novel Retinal Disease Drug Candidate




MasterControl Spotlights QMS for Pharmaceutical Companies at INTERPHEX 2017

Tue, 21 Mar 2017 08:00:00 EDT

NEW YORK, NY--(Marketwired - Mar 21, 2017) - MasterControl Inc., a global provider of enterprise software solutions for life science and other regulated companies, today announced it will be highlighting the benefits of advanced quality management systems (QMS) for pharmaceutical companies at the INTERPHEX 2017 conference to be held March 21-23 in New York City.




L-DOS47 Phase I Study Results To Be Presented at the 9th International Conference of Contemporary Oncology

Tue, 21 Mar 2017 08:00:00 EDT

TORONTO, ON--(Marketwired - Mar 21, 2017) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that results from the Phase I L-DOS47 study will be presented at the upcoming 9th International Conference of Contemporary Oncology meeting in Poznan, Poland from the 22nd to the 24th of March, 2017. The leading theme of the conference is genome-based precision oncology -- direct targeting and immune-targeting of cancer.




Canabo Medical Inc. Opens New Clinic in Chilliwack, BC

Tue, 21 Mar 2017 08:00:00 EDT

VANCOUVER, BC--(Marketwired - March 21, 2017) - Canabo Medical Inc. (TSX VENTURE: CMM) (OTCQB: CAMDF) ("Canabo" or the "Company") is pleased to announce it has opened a clinic in Chilliwack, British Columbia. The Company's BC operations will be led by Dr. Gwyllyn Goddard who has over 9 years' experience in authorizing medical cannabis, specializes in chronic disease and management and is an active researcher in the Company's current observational study. This opening represents the Company's first clinic in British Columbia and expands the Company's clinic footprint from coast-to-coast.




Pressure BioSciences, Inc. to Discuss Fourth Quarter and Fiscal Year 2016 Financial Results and Provide Business Update

Tue, 21 Mar 2017 07:55:43 EDT

SOUTH EASTON, MA--(Marketwired - Mar 21, 2017) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Fourth Quarter and Fiscal Year 2016 financial results and to provide a business update. Anyone interested may listen to the teleconference by telephone (live) or through a replay by telephone or on the Company's website.




Upcoming Xtalks Webinar to Examine Formulating Amorphous Solid Dispersions: Bridging Particle Engineering and Formulation

Tue, 21 Mar 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - March 21, 2017) - During a live broadcast on Thursday, April 6, 2017, experts from Hovione will highlight the importance of an integrated development of both the spray dried intermediate (SDI) and the formulation. By bridging particle engineering of the drug product intermediate and the final dosage formulation, one can perform a concurrent optimization of drug performance and process performance, with respect to yield, throughput and process robustness throughout the process train. This is achieved by using QbD tools, such as Design of Experiments and mechanistic modelling, to integrate all the competing factors in formulation development, and establish the optimal processing conditions and material attributes.




Delivra Signs Exclusive Licensing Deal with Dosecann for Cannabis Oil Formulations in Metered Dose Formats

Tue, 21 Mar 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - March 21, 2017) - Delivra Corp. (TSX VENTURE: DVA) ("Delivra" or the "Company"), Dosecann Inc. ("Dosecann") and ARA-Avanti Rx Analytics Inc. ("Avanti") announced today a strategic partnership to develop a unique suite of standardized products for the medical cannabis research, development, and commercialization markets.




Zecotek Provides Update to LFS Crystal MOU with Chinese PET OEM

Tue, 21 Mar 2017 03:15:00 EDT

SINGAPORE--(Marketwired - March 21, 2017) - Zecotek Photonics Inc. (TSX VENTURE: ZMS) (FRANKFURT: W1I) (OTC PINK: ZMSPF), a developer of leading-edge photonics technologies for industrial, healthcare and scientific markets, is pleased to provide an update to the memorandum of understanding (MOU) with the Chinese medical OEM to purchase LFS scintillation crystals for a new line of medical scanners as previously announced on March 23, 2016. The MOU called for Zecotek's wholly owned subsidiary Zecotek Imaging Systems to supply LFS crystal elements to the Chinese OEM for up to 200 positron emission tomography (PET) medical scanners over the next 5 years, for clinics and hospitals across China. Due to the changing medical scanner landscape in China, the proposed agreement now calls for the Chinese OEM to purchase LFS crystal based arrays through the Shanghai EBO Optoelectronics Company (EBO).




Nephros Reports 2016 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mon, 20 Mar 2017 17:44:41 EDT

Anticipates 100% Year Over Year Growth in Medical Device Filters; Anticipates Reaching Cash Flow Positive in Three to Six Months




Med Ad News Announces Finalists for the 2017 Manny Awards and Names Dana Maiman, CEO/President of FCB Health, as Industry Person of the Year

Mon, 20 Mar 2017 15:57:22 EDT

LIVINGSTON, NJ--(Marketwired - March 20, 2017) - Med Ad News, the leading pharmaceutical business and marketing publication, announces the nominees for the 28th Annual Manny Awards, celebrating the best in pharmaceutical and healthcare advertising, and announces Dana Maiman as the Industry Person of the Year. The Manny Awards annual gala event celebrates creative excellence in healthcare advertising and communications. More than 600 industry peers are expected to join Med Ad News in honoring winners across 20 total award categories, including the year's Most Creative Agency, Most Admired Agency, Best Launch Campaign, Agency of the Year I, II and III, and more. The Manny Awards ceremony will be held on Thursday, April 20, 2017, at Pier Sixty at Chelsea Piers in New York City.